APML04 | The Australasian Leukaemia and Lymphoma Group

DOI number	10.58109/yen7-mb13
Publisher	Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)	Australasian Leukaemia and Lymphoma Group (ALLG) Harry Iland (Royal Prince Alfred Hospital)
Date Made Available	2023
Dataset	Individual participant data (IPD) in aggregate form
Description of Dataset	Dataset includes: Data on 200 patients with acute non-lymphocytic leukaemia High dose Ara-C daunorubicin and VP16-213 (HIDAC-37) versus conventional dose and complete remission in adults Remission duration/survival Toxicity of two treatment arms Prognostic variables Cytogenetics
Funding	Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)	Cancer therapy (excl. chemotherapy and radiation therapy)
ANZCTR Reference	ACTRN12605000070639
Publication(s)	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era
Dataset Access	Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au